The objective of this study was to develop an optimal iron oxide enhanced lymph node MRI protocol and robust image analysis using pre-and-post ferumoxytol T2 and T2* scans in canine patients with HNC. Since those pet patients are naturally prone to HNC, they can serve as a great translational platform for development of novel non-invasive imaging modalities for LN staging and metastasis and to guide anti-lymphangiogenic therapies. The results indicate that Ferumoxytol can be used as T2 negative contrast agent for non-invasive LN staging 48 hrs post-injection. SI normalization should be performed to a phantom or to the brain.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords